The 36-month beta value for YMAB is at 0.57. Analysts have varying views on the stock, with 7 analysts rating it as a “buy”, 1 rating it as “overweight”, 0 as “hold”, and 1 as “sell”.
The public float for YMAB is 34.02M, and currently, shorts hold a 7.80% of that float. The average trading volume for YMAB on July 04, 2025 was 229.25K shares.
YMAB stock’s latest price update
Y-Mabs Therapeutics Inc (NASDAQ: YMAB)’s stock price has increased by 0.94% compared to its previous closing price of $4.26. However, the company has seen a -10.42% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-28 that PRINCETON, N.J., May 28, 2025 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radiopharmaceuticals, and commercial stage antibody-based therapeutic products for the treatment of cancer, today announced that the Company plans to highlight progress across its Radiopharmaceutical Business Unit during a virtual R&D update to be held today, Wednesday, May 28, 2025 at 8:00 a.m. ET.
YMAB’s Market Performance
YMAB’s stock has fallen by -10.42% in the past week, with a monthly drop of -11.70% and a quarterly drop of -10.42%. The volatility ratio for the week is 5.24% while the volatility levels for the last 30 days are 7.71% for Y-Mabs Therapeutics Inc The simple moving average for the last 20 days is -9.81% for YMAB stock, with a simple moving average of -45.08% for the last 200 days.
Analysts’ Opinion of YMAB
Many brokerage firms have already submitted their reports for YMAB stocks, with BofA Securities repeating the rating for YMAB by listing it as a “Underperform”. The predicted price for YMAB in the upcoming period, according to BofA Securities is $3 based on the research report published on April 22, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see YMAB reach a price target of $23. The rating they have provided for YMAB stocks is “Outperform” according to the report published on November 18th, 2024.
Truist gave a rating of “Buy” to YMAB, setting the target price at $21 in the report published on June 28th of the previous year.
YMAB Trading at -3.39% from the 50-Day Moving Average
After a stumble in the market that brought YMAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.31% of loss for the given period.
Volatility was left at 7.71%, however, over the last 30 days, the volatility rate increased by 5.24%, as shares sank -13.31% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.94% upper at present.
During the last 5 trading sessions, YMAB fell by -10.42%, which changed the moving average for the period of 200-days by -68.70% in comparison to the 20-day moving average, which settled at $4.77. In addition, Y-Mabs Therapeutics Inc saw -63.65% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at YMAB starting from Rossi Michael J, who sold 3,917 shares at the price of $5.20 back on Mar 07 ’25. After this action, Rossi Michael J now owns 137,083 shares of Y-Mabs Therapeutics Inc, valued at $20,368 using the latest closing price.
Gad Thomas, the CHIEF BUSINESS OFFICER of Y-Mabs Therapeutics Inc, sale 10,810 shares at $5.23 during a trade that took place back on Mar 07 ’25, which means that Gad Thomas is holding 202,721 shares at $56,536 based on the most recent closing price.
Stock Fundamentals for YMAB
Current profitability levels for the company are sitting at:
- -0.35% for the present operating margin
- 0.82% for the gross margin
The net margin for Y-Mabs Therapeutics Inc stands at -0.32%. The total capital return value is set at -0.33%. Equity return is now at value -29.93%, with -23.93% for asset returns.
Based on Y-Mabs Therapeutics Inc (YMAB), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -31.75.
Currently, EBITDA for the company is -30.67 million with net debt to EBITDA at 1.96. When we switch over and look at the enterprise to sales, we see a ratio of 1.52. The receivables turnover for the company is 5.0for trailing twelve months and the total asset turnover is 0.79. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.77.
Conclusion
In conclusion, Y-Mabs Therapeutics Inc (YMAB) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
